Pfizer to acquire biotech firm Arena for $6.7 billion. Arena’s portfolio includes several development-stage drug candidates, including lead candidate etrasimod, an oral, selective sphingosine 1-phosphate receptor modulator currently in Phase 3 clinical trials for ulcerative colitis and a Phase 2/3 trial for Crohn’s disease.